HomeTrialNCT06544616
🔬NCT06544616Phase 2ACTIVE NOT RECRUITING

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Study Summary

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment498 participants
Primary Completion
Lead SponsorJanssen Pharmaceutica N.V., Belgium
Data Retrieved2026-04-11 02:55:31.549771+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.